Better Health for All
20
Alector's core mission is entirely focused on developing therapies for severe neurodegenerative diseases, including Alzheimer's, Frontotemporal Dementia, Parkinson's, Gaucher Disease, and Lewy Body Dementia, aiming to slow progression or prevent their occurrence.
1
The company's entire business is dedicated to research and development for health improvement, driven by insights in human genetics, neuroscience, and immunology, and applying novel technologies like the proprietary Alector Brain Carrier (ABC) and siRNA therapies.
2
This includes a $700 million upfront payment and up to $1.5 billion in potential milestones from GSK for collaboration, and a $1.7 million grant from The Michael J. Fox Foundation.
3
Alector has no revenue from products with established negative health outcomes. The company has demonstrated transparency by publicly disclosing negative clinical trial results, including latozinemab failing its Phase III INFRONT-3 trial
4
and AL002 failing a Phase II trial, and plans to present detailed findings at medical meetings. Alector provides dedicated mental health benefits for its employees
5
, and its therapeutic focus on diseases like dementia and frontotemporal dementia addresses conditions with significant mental health implications.
6
Fair Money & Economic Opportunity
0
Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases.
1
The company does not offer lending, insurance, deposit services, or any other consumer financial products. Consequently, all Key Performance Indicators related to 'Fair Money & Economic Opportunity' are not applicable to its business operations. While Alector aims to reduce healthcare costs through its technology and provides stock-based compensation to employees, these activities do not align with the rubric's definitions for fair pricing of financial products, wealth-building outcomes for financial service customers, or community finance reinvestment. Similarly, the company's corporate loan agreements
2
and biomarker data initiatives
3
fall outside the scope of consumer debt products or financial data accessibility.
Fair Pay & Worker Respect
60
All full-time employees and their dependents receive employer-funded health insurance and other benefits, including dedicated mental health, fertility, and caregiving programs.
1
The CEO to median employee pay ratio for 2024 was approximately 13.5x, with the CEO's total compensation at $3,666,341
2
and the median employee pay at $270,712.
3
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any information regarding Alector, Inc.'s fair trade and ethical sourcing practices
1
. Specifically, there is no data available for fair trade certification share
2
, audit frequency for suppliers
3
, forced or child labor incidents
4
, supply chain traceability coverage
5
, remediation speed for violations
6
, ethical clause coverage in supplier contracts
7
, materials risk index
8
, or supplier diversity spend
9
.
Honest & Fair Business
-40
As of March 31, 2025, 7 out of 9 (77.77%) Alector, Inc. directors are independent under Nasdaq rules.
1
The Audit Committee reviews and monitors related party transactions and potential conflicts of interest.
2
The company provides an anonymous hotline for employees to submit concerns directly to the General Counsel and Head of Compliance.
3
, with the Audit Committee overseeing procedures for confidential, anonymous submissions regarding accounting or auditing matters.
4
A Code of Conduct applies to all employees, officers, and directors.
5
An insider trading policy, amended December 2024, prohibits hedging and pledging.
6
A Compensation Recovery Policy was adopted in September 2023 per SEC and Nasdaq requirements.
7
The Audit Committee reviews and monitors compliance with the Code of Business Conduct and Ethics
8
and assesses the adequacy and effectiveness of legal, regulatory, and ethical compliance programs.
9
Kind to Animals
-60
Alector, Inc. conducts animal testing, as indicated by its 'Animal Testing Yes' status.
1
Preclinical studies for AL002 involved the use of 68 cynomolgus monkeys across a 4-week GLP toxicology study, a non-GLP dose range–finding study, and a non-GLP interval study.
2
All procedures complied with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.
3
The company also utilized in vitro cell-based assays using human macrophages to assess AL002 activity and performed RNA sequencing on BAC transgenic mice.
4
No War, No Weapons
0
Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases such as Alzheimer's and frontotemporal dementia
1
. Its core business activities, including clinical trials and research, are entirely within the medical and pharmaceutical sectors
2
. There is no evidence in the provided articles of the company being involved in arms manufacturing, military contracts, sales to embargoed regimes, or any other activities related to war or weapons
3
. While one article noted that a proprietary blood-brain barrier platform could potentially be considered dual-use technology
4
, there is no indication of R&D investment or application for military purposes
5
. A $1.7 million grant received for collaborative research on Parkinson's disease is a medical initiative, not a peacebuilding or disarmament effort
6
.
Planet-Friendly Business
0
Alector, Inc. is a clinical-stage biotechnology company whose operations involve the use of hazardous and flammable materials, including chemicals, biological, and radioactive materials, and produce hazardous waste.
1
The company and its contract manufacturers and suppliers are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements.
2
A third-party ESG assessment, last updated in October 2022, indicates negative environmental impacts, with specific negative scores for GHG emissions (-0.41), non-GHG emissions (-0.10), scarce natural resources (-0.02), biodiversity (-0.02), and waste (-0.38).
3
Sustainalytics rated Alector's ESG Risk Rating as 33.4 (High), placing it 517 out of 847 in the Pharmaceuticals industry.
4
However, no specific quantitative data, such as total greenhouse gas emissions in tCO₂e, percentage of renewable energy used, water withdrawal per revenue, waste diversion rates, or the number of environmental compliance violations, is provided to assess the company against the detailed planet-friendly business metrics.
Respect for Cultures & Communities
0
The provided article focuses on Alector's company culture, diversity, and inclusion, including workforce demographics, employee benefits, volunteer initiatives, and company-wide events.
1
It explicitly states that no data relevant to community engagement, cultural impact assessments, or similar metrics is provided.
2
Therefore, there is no evidence to assess ALEC.US against the 'Respect for Cultures & Communities' value based on the given information.
Safe & Smart Tech
10
Alector's privacy policy, last updated January 16, 2024,
1
outlines comprehensive user data controls for California and EU/UK residents. California residents have rights to know, access, portability, deletion (with exceptions), correction, opt-out of sale/sharing, and to limit the use of sensitive personal information.
2
EU/UK residents have rights to access, correct, erase, restrict use, and withdraw consent.
3
The policy explicitly addresses compliance with the California Consumer Privacy Act (CCPA), California Privacy Rights Act (CPRA), and EU/UK data rights.
4
The company is also subject to HIPAA and other U.S. and foreign data protection laws.
5
Alector implements data minimization where practicable
6
and retains personal information only as long as necessary.
7
The company states it does not sell personal information to advertisers or third parties for financial compensation
8
and has not sold or shared personal information for cross-contextual behavioral advertising in the past 12 months.
9
Prohibited conduct includes collecting personal information without consent.
10
Password-protection is implemented where practicable.
11
The Audit Committee oversees cybersecurity risks,
12
and the company invests in data and IT infrastructure protection.
13
Alector disclaims warranties that its website will be free of errors or harmful components,
14
and has experienced cyberattacks in the past.
15
Zero Waste & Sustainable Products
-20
Alector has implemented waste reduction initiatives, including a Green Team that educates employees on reducing waste, water use, and single-use consumables.
1
The company segregates waste streams like containers, food waste, plastics, and styrofoam on-site for recycling and composting.
2
Alector's South San Francisco headquarters is LEED certified, and the company holds San Mateo County and California “Green Business” certifications.
3
The company uses hazardous and flammable materials, generating hazardous waste, and contracts with third parties for its disposal.
4
No waste disposal violations are mentioned in the provided documents.
5